- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03010332
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
This is an expanded access protocol designed to provide access of ATA230 to subjects with CMV viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment options. This study will enroll subjects regardless of the underlying susceptibility to CMV, including allogeneic hematopoietic cell transplant (alloHCT), solid organ transplant (SOT), human immunodeficiency virus (HIV), other immunocompromised states, and immune competent subjects who require therapy. Subjects must have active CMV viremia or disease for ≥ 2 weeks despite treatment with antiviral therapy or must be intolerant to antiviral therapy due to treatment-related toxicity or comorbidities such as renal insufficiency or myelosuppression.
ATA230 will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) ATA230 at a dose of 1×10^6 cells/kg (with an acceptable range of 0.8-1.0×10^6 cells/kg) on Days 1, 8, and 15, followed by observation through Day 35.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A subject will be considered eligible to participate in the study if the following inclusion criteria are satisfied:
- Has a clinically documented condition associated with CMV disease (eg, interstitial pneumonia, hepatitis, encephalitis, retinitis, colitis) or microbiological evidence of CMV viremia or tissue invasion with CMV infection (as determined by viral culture or levels of CMV DNA in blood or body fluids)
The CMV disease or CMV viremia is characterized by at least one of the following:
- CMV disease is persistent or clinically progressing despite ≥ 2 weeks of antiviral therapy
- CMV viremia/disease is persistent or increasing (determined by quantitation of blood CMV DNA) despite ≥ 2 weeks of antiviral therapy
- A genetic mutation associated with antiviral drug resistance is present
- Unable to continue antiviral drugs due to drug-associated toxicity.
- No other comparable or satisfactory therapies are available for treatment of CMV
- Not eligible for any other trials supporting development of ATA230
- For subjects who received an alloHCT, the underlying disease for which the alloHCT was performed is in morphologic remission
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× the upper limit of normal (ULN) and total bilirubin < 2.5×ULN unless caused by CMV
- Availability of appropriate ATA230 cell lot (ie, HLA partially-matched and restricted CMV-CTLs)
- Subject or subject's representative is willing and able to provide written informed consent
Exclusion Criteria:
A subject will not be eligible to participate in the study if any of the following criteria are met:
- Receiving concomitant investigational therapy (co-enrollment in a non-interventional study or a study for follow-up or sample collection only is permitted)
- Need for antimetabolite agents (eg, methotrexate), or extracorporeal photopheresis
- Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to the first dose of ATA230 (on Day 1 of Cycle 1)
- Need for vasopressor or ventilator support
- Pregnancy, except when ATA230 is clearly needed
- Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception
- Inability to comply with study procedures
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Willis Navarro, MD, Atara Biotherapeutics
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Hematopoietic Stem Cell Transplant
- Human Immunodeficiency Virus
- Cytomegalovirus
- CMV
- Hematopoietic Cell Transplant
- allogeneic
- Solid Organ Transplant
- CMV Infection
- Cytomegalovirus Viremia
- Cytomegalovirus Infection
- Cytomegalovirus Disease
- CMV syndrome
- Cytomegalovirus syndrome
- CMV disease
- CMV viremia
- third-party
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATA230-EAP-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV Viremia
-
Hospital Israelita Albert EinsteinRecruiting
-
University of MinnesotaCompletedCMV Viremia | EBV ViremiaUnited States
-
University of Alabama at BirminghamRecruitingCmv Congenital | CMV ViremiaBrazil
-
Hospital do Rim e HipertensãoEnrolling by invitationCMV Infection | CMV ViremiaBrazil
-
University Medical Centre LjubljanaRecruiting
-
Memorial Sloan Kettering Cancer CenterRecruitingCMV Infection | Persistent CMV ViremiaUnited States
-
Peking University People's HospitalRecruitingTransplantation Infection | CMV ViremiaChina
-
University of Wisconsin, MadisonUniversity of Wisconsin Carbone Cancer Center (UWCCC)RecruitingCytomegalovirus Infections | Opportunistic Infections | CMV Infection | CMV ViremiaUnited States
-
Peking University People's HospitalUnknownAcute Leukemia | Hematopoietic Stem Cell Transplantation | CMV ViremiaChina
-
Banc de Sang i TeixitsHospital Universitario La Fe; Vall d'Hebron Institute of OncologyCompletedCMV Viremia | Immunosuppression-related Infectious DiseaseSpain
Clinical Trials on Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia and other conditionsUnited States
-
M.D. Anderson Cancer CenterMiltenyi Biotec B.V. & Co. KGCompletedLymphoma | LeukemiaUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...TerminatedBrain Cancer | Glioblastoma Multiforme | GBMUnited States
-
New York Medical CollegeJohns Hopkins University; Children's Hospital of Philadelphia; Washington University... and other collaboratorsRecruitingPrimary Immune Deficiency Disorder | Cytomegalovirus InfectionsUnited States
-
Sumithira VasuRecruitingCytomegalovirus | Adenovirus | Donor | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Solid Organ Transplantation RecipientUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cytomegaloviral InfectionUnited States
-
Milton S. Hershey Medical CenterCompleted
-
New York Medical CollegeJohns Hopkins University; University of Colorado, Denver; Children's Hospital... and other collaboratorsRecruitingPrimary Immune Deficiency Disorder | AdenovirusUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)Unknown
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | ImmunocompromisedUnited States